Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas and in Individuals Living in Onchocerciasis Endemic Areas With High Levels of Lymphatic Filariasis Co-endemicity Receiving Concomitant Albendazole

PHASE3CompletedINTERVENTIONAL

Enrollment

12,997

Participants

Timeline

Start Date

May 3, 2021

Primary Completion Date

September 27, 2024

Study Completion Date

September 27, 2024

Conditions

Onchocerciasis

Interventions

DRUG

Moxidectin

2 mg tablets, encapsulated for blinding

DRUG

Ivermectin

3 mg tablets, encapsulated for blinding

DRUG

Albendazole

400 mg tablets

Trial Locations (2)

Centre Suisse de Recherches Scientifiques en Coˆte d'Ivoire, Abidjan

Centre de Recherche pour les Maladies Tropicales Negligees, Rethy

All Listed Sponsors

lead

Medicines Development for Global Health

OTHER